AlphaLiquid*100 LABX Ultrasensitive ctDNA Liquid Biopsy Platform for Comprehensive Genomic Profiling AlphaLiquid®100 is a minimally invasive liquid biopsy test that offers a personalized guide for treatment strategies in advanced solid-tumor patients, including tumor genotyping, therapy selection and response monitoring Ultrasensitive variant detection based on 50,000x sequencing depth and >8,000x error- corrected unique molecule coverage AlphaLiquid®100 detects trace amounts of Circulating tumor DNA (ctDNA) in the blood and evaluates genomic alterations and biomarkers. across 118 genes (including 14 HRR genes and fusions in 10 genes). The test is available as a clinical send-out service or through a cloud-based remote testing platform. Fast turnaround time of 7-10 days Proven performance in >6,000 clinical samples Reliable tissue concordance rates of 90-95% 2ecifications Targeted hybrid capture NGS based on proprietary HQS™ technology VAN ET ciccMicicgaml 10m! of whole blood cfONAnput Amount [EER Coury 466kb Single nucleotide variants (SNVs), Insertions & Deletions (Indels}, Copy Number Gitrieeetibedieks)) Alterations (CNAs), Fusions, Homologous Recombination Repair (HRR) Peers ey wy) | Microsatellite Instability (MSI), Tumor Mutation Burden (TMB) PIE e ota oom ("Based on 30ng input cfONA) roe) Seccr eee eae ee esata roe) Sensitivity Soren 201% 95% SNVs 20.03% 299.9% 205% 99% 201% 95% Indels 20.01% 299.9% 205% 99% Fusions > 0.05% 20.2% 95% 100% Mela 222 copies 224 copies 99% 100% ae eae 1.8 copies 16 copies 99% 100% IMBpoxGene Panel AlphaLiquid®100 gene panel includes 18 of the most clinically relevant genes in all solid tumors, including 34 druggable targets, 15 HRR genes and 434 MSI markers". (Druggable targets) Ser Ez) Fusions (10) ABI AKT AKI29 ALK APC OAR ARAFAKT.CHEKI" ALB ALK ARIDIA ATM* BARDI* BRAF* BRCAI* BRCA2*BRIPI* —AR_—CHEK2* PDGFRA BCR STK — CBL_—- CONDI. CCND2.CCNET.-«CD274. © CDH. ~—ATM. EGFR PIK3CA". RAF CDKI2* CDK% ~—« CDK. -—«CDKN2A. CEBPA CHEKI* CHEK2* BARDI"” ERBB2* PPP2R2A EGFR SFIR-CTNNBI DDR2-DPYD —EGFR* ERBB2" ERBBS —BRAF_FANCL* RADSIBY — FOFR2* ESR) FANCL* FEXW7 FGFRI FGFR2* FCFRS* FLTS. ~—«BRCAT*FGFRI RADSIC* —FGFR3* CATA GNATI.GNAQ_GNAS-— RAS IDHT*—IDH2_—BRCA2* FGFR2* RADSID* —NTRKI* (CFR = JAK2—JAK3.-—«KOMGA.—KDR—KEAPI.—KIT* ~—BRIPIY_FGFRS* RADSAL* —NTRK2* KRAS* —MAP2KI MAB2K2 MAPKI -MAPKS = MDM2— MET" CCNDI. «KDR RAFT RET* MLHT = MBL MSH2- MSHG = «MTOR = MYC MYCN CCND2- KIT. RET Rosi NF -NE2_—-NFE2L2.-NOTCHT NPM? —NRAS* NTRKI* CNET KRAS* NTRK2 NTRK3* PALB2* PDCDILG2 PDGFRA* PDGFRB PIK3CA* CD27 MAPKI PIKSRI —PMS2 PRP2RIA PPP2R2A PTEN PTPNIT RADSIB* —CDKI2"_ MDM2, RADSIC* RADSID* RADS4L* RAFT RBI RET* RHE = CDK4# MET RHOA —-RITI_—«RNF43—« OST. RUNXT.--SETD2. SMADS =< CDK6.— MYC. SMO STAG2_—STKN—TCF7L2.—«‘TERT = TOP2A_—«TRS3._—=—«CDKN2A_ MYCN TSC! TSC2.—sU2AFI. sve sural me Monitoring of Therapy Response Longitudinal ctDNA profiling using AlphaLiquid®100 can help overcome spatial heterogeneity and provide a real-time representation of the tumor's systemic genomic profile, which enables early detection of ctDNA relapse as well as emergence of new mutations", Figure: Tumor Response Map (Dynamic Changes of Tumor Burden represented by ctDNA Variants) mz snare . _ nec oscn24rter 3637 i eae Pee ——= s. i ar ~ a Psspcnaites spe MS, rf mn ae eee ae Re-emergence of baseline ctDNA mutations Venas ror erst Sarthe eciooaeal TS Wyeccricy amo een progression By median of 33 months coos variant detection Detection of new resistance mutations enable evaluation of i 1 i \ \ \therapy resistance mechanisrns ° 3 6 ° B 1s Months Reference: Kim eto 2022 British Journol of Cancer. For More Information: Tel: (02) 8541-8448 | Email: sales@labxasia | Visit: wwwilabxasia LABX (02) 8529-1070 info@labxasia Ee eearesy Labx Corp | Clipp Center, Th Ave., Cor. 39th St,, BGC 1634, Philippines IMBox